logo-loader
viewNuformix PLC

Nuformix PLC focused on licensing agreements and further fee-for-service work

Nuformix (LON:NFX) chairman Dr Chris Blackwell speaks to Proactive following the release of its results to March 2020. He says the focus over the year has been towards the treatment of patients with fibrosis and the development of its anti-fibrotic candidate NXP002. Blackwell adds that he's excited about two new recent revenue generating collaborations they've agreed with Ebers Tech and VistaGen Therapeutics.

Quick facts: Nuformix PLC

Price: 2.75 GBX

LSE:NFX
Market: LSE
Market Cap: £14.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nuformix PLC named herein, including the promotion by the Company of Nuformix PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Nuformix PLC has 'validated its platform' as it works on 'immediate...

Dan Gooding, chief executive of Nuformix (LON:NFX), caught up with Proactive London's Andrew Scott  soon after raising £1.25mln to help advance its pipeline of drugs. Gooding says the fundraise strengthens its position as negotiations continue in Asia for its NXP2 asset.

on 29/11/19

2 min read